The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Natural products as IL‐6 inhibitors for inflammatory diseases: Synthetic and SAR perspective
Abstract
Interleukin‐6 (IL‐6), a pleiotropic cytokine, plays a pivotal role in the pathophysiology of various diseases including diabetes, atherosclerosis, Alzheimer's disease, multiple myeloma, rheumatoid arthritis, and prostate cancer. The signaling pathways associated with IL‐6 offer promising targets for therapeutic interventions in inflammatory diseases and IL‐6‐dependent tumors. Although certain anti‐IL‐6 monoclonal antibodies are currently employed clinically, their usage is hampered by drawbacks such as high cost and potential immunogenicity, limiting their application. Thus, the imperative arises to develop novel small non‐peptide molecules acting as IL‐6 inhibitors. Various natural products derived from diverse sources have been investigated for their potential to inhibit IL‐6 activity. Nevertheless, these natural products remain inadequately explored in terms of their structure‐activity relationships. In response, our review aims to provide syntheses and structure activity perspective of natural IL‐6 inhibitors. The comprehensive amalgamation of information presented in this review holds the potential to serve as a foundation for forthcoming research endeavors by medicinal chemists, facilitating the design of innovative IL‐6 inhibitors to address the complexities of inflammatory diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that IL-6 promotes the proliferation of MM cells, blocking IL-6 is considered a potential strategy for MM treatment [110–112].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [112]
Citations
Cites
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Research works printed but not linked: 89
- 10.3109/08830189809042997 · DOI · Paper page
- 10.1126/science.1411569 · DOI · Paper page
- 10.4049/jimmunol.151.3.1456 · DOI
- 10.1172/JCI117990 · DOI
- 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P · DOI
- 10.1182/blood.V76.12.2599.2599 · DOI
- Tanaka T, 2015, Molecular Biology of B Cells (Second Edition), 515
- 10.1136/gutjnl-2017-314562 · DOI · Paper page
- 10.1093/annonc/mdv309 · DOI
- 10.1093/rheumatology/ken468 · DOI
- 10.1111/bcp.13641 · DOI
- 10.1002/art.39722 · DOI
- 10.1182/blood-2013-12-546374 · DOI
- 10.1136/annrheumdis-2013-204963 · DOI · Paper page
- 10.1136/annrheumdis-2013-205137 · DOI · Paper page
- 10.1002/art.39249 · DOI · Paper page
- 10.1038/s41586-020-2008-3 · DOI · Paper page
- 10.1007/s40290-020-00342-z · DOI
- 10.1016/j.bmc.2020.115327 · DOI
- 10.1016/j.cytogfr.2012.09.001 · DOI
- 10.1021/acs.jmedchem.2c01957 · DOI
- 10.3390/ijms12129481 · DOI
- 10.1021/jm500901e · DOI
- 10.1021/np100686a · DOI
- 10.1016/j.bmcl.2007.10.009 · DOI
- 10.7164/antibiotics.49.1091 · DOI
- 10.1021/jm401144z · DOI
- 10.1021/ja9938074 · DOI
- 10.1016/S0040-4039(00)00937-0 · DOI
- 10.1016/S0040-4039(00)00939-4 · DOI
- 10.1021/ol017058i · DOI
- 10.1016/j.tetlet.2006.07.083 · DOI
- 10.1021/ol026015e · DOI
- 10.1021/ol062919e · DOI
- 10.1021/ja3032345 · DOI
- 10.1177/1934578X1300800710 · DOI
- 10.1021/ja5117556 · DOI
- 10.1080/00397911.2016.1185525 · DOI
- 10.1021/acs.orglett.8b01254 · DOI
- 10.1021/acs.jpcb.7b05732 · DOI
- 10.1021/bi050439 · DOI
- 10.1016/j.bmcl.2006.01.107 · DOI
- 10.1016/j.bmcl.2016.01.016 · DOI
- 10.4049/jimmunol.1402908 · DOI
- 10.5713/ajas.19.0463 · DOI
- 10.1016/j.tet.2014.10.015 · DOI
- 10.1248/bpb.29.220 · DOI
- 10.1177/1534735406291984 · DOI
- 10.1016/j.intimp.2006.10.002 · DOI
- 10.1016/j.tetlet.2015.08.045 · DOI
- 10.1016/j.fct.2017.05.042 · DOI
- 10.3389/fphar.2022.920435 · DOI
- 10.1002/chem.201304304 · DOI
- 10.1039/C7RA03551A · DOI
- 10.1039/C8OB03102A · DOI
- 10.1021/acs.jnatprod.0c00697 · DOI
- 10.1038/s41598-018-36925-9 · DOI
- 10.1021/acs.jafc.5b04781 · DOI
- 10.1002/jcb.23312 · DOI
- Park J‐H, 2014, Anti‐adipogenic activity of ailanthoidol on 3T3‐L1 adipocytes, Biomed Sci Lett, 20, 62
- 10.1186/1476-9255-10-1 · DOI
- 10.1016/j.bmcl.2014.10.077 · DOI
- 10.1055/s-2007-990796 · DOI
- 10.1016/j.jep.2020.113104 · DOI
- 10.1248/cpb.59.885 · DOI
- 10.1007/s10787-018-0503-z · DOI
- 10.1021/acs.jnatprod.8b00596 · DOI
- 10.1016/j.ejphar.2019.172699 · DOI
- 10.1155/2020/3476212 · DOI
- 10.1515/pac-2017-0201 · DOI
- 10.1021/jf100421w · DOI
- 10.1016/j.procbio.2016.09.003 · DOI
- 10.1016/j.bmcl.2019.04.053 · DOI
- 10.1021/acs.oprd.9b00091 · DOI
- 10.1039/C8GC03661F · DOI
- 10.1021/np0200360 · DOI
- 10.1021/np2008957 · DOI
- 10.1021/np500803e · DOI
- 10.1021/np500760v · DOI
- 10.1021/acs.jafc.7b03712 · DOI
- 10.1590/1414-431x202010109 · DOI
- 10.1016/j.biopha.2018.02.009 · DOI
- 10.4155/fsoa-2017-0008 · DOI
- 10.1016/j.phymed.2019.152848 · DOI
- 10.1021/acs.jafc.6b03407 · DOI
- Di L, 2015, Drug‐like properties: concepts, structure design and methods from ADME to toxicity optimization
- 10.3390/molecules26030553 · DOI
- 10.1602/neurorx.2.4.554 · DOI
- 10.1602/neurorx.2.1.86 · DOI
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Metadata
- Authors
- Harmalkar, D. S., Sivaraman, A., Nada, H., Lee, J., Kang, H., Choi, Y., & Lee, K.
- Affiliations
- Korea University (KR)
- Dongguk University (KR)
- Corresponding author
- Choi, Yongseok
- Lee, Kyeong
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2024-02-02
- Volume
- 44
- Issue
- 4
- Pages
- 1683-1726
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W4391484807
- Cited by
- 23
- References
- 1
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 8
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medicinal Research Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (NRF 2018R1A5A2023127, 2023R1A2C3004599)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Bioactive natural compounds
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- interleukin-6, IL-6 inhibitors, natural products, structure-activity relationship, small molecule inhibitors, anti-inflammatory agents, inflammatory diseases, IL-6 signaling, medicinal chemistry
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Biological Products, Humans, Inflammation, Structure-Activity Relationship, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review